Tvardi Therapeutics, Inc.(TVRD)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Rank #2,903 of 2,962 stocks
Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.
TVRD Stock Analysis & AI Quality Score
Data updated 2026-09-11AI stock analysis and institutional research for Tvardi Therapeutics, Inc. (TVRD), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores TVRD at 11.2/100 on a 32-signal composite quality model, placing it at rank #2,903 of 2,962 stocks — the bottom half of the AI-ranked universe. TVRD trades on the Nasdaq exchange and files with the SEC under CIK 1346830. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate TVRD daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Tvardi Therapeutics, Inc. directly from SEC EDGAR. Tvardi Therapeutics, Inc.'s 13F Pro composite quality score has ranged between 8 and 11 since 2025, currently 11.2 — a stable long-term trajectory across 8 quarterly and live scoring snapshots.
Net Income
Q1 2026
$-6.8M
Get alerted when TVRD's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for Tvardi Therapeutics, Inc. including:
More Healthcare Companies
View all Healthcare →Put TVRD on your watchlist
Track score changes the day Tvardi Therapeutics, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is TVRD a good stock to buy?
13F Pro's AI-powered analysis of Tvardi Therapeutics, Inc. (TVRD) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for TVRD are available on the TVRD stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. TVRD is classified as a small company.
Which hedge funds own TVRD?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling TVRD. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Tvardi Therapeutics, Inc.'s investment landscape.